139 related articles for article (PubMed ID: 33298310)
1. Immunogenomic landscape of gynecologic carcinosarcoma.
Gotoh O; Kiyotani K; Chiba T; Sugiyama Y; Takazawa Y; Nemoto K; Kato K; Tanaka N; Nomura H; Hasegawa K; Fujiwara K; Takamatsu S; Matsumura N; Noda T; Mori S
Gynecol Oncol; 2021 Feb; 160(2):547-556. PubMed ID: 33298310
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma.
Gotoh O; Sugiyama Y; Takazawa Y; Kato K; Tanaka N; Omatsu K; Takeshima N; Nomura H; Hasegawa K; Fujiwara K; Taki M; Matsumura N; Noda T; Mori S
Nat Commun; 2019 Oct; 10(1):4965. PubMed ID: 31672974
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
4. Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma?
Chiyoda T; Tsuda H; Tanaka H; Kataoka F; Nomura H; Nishimura S; Takano M; Susumu N; Saya H; Aoki D
Genes Chromosomes Cancer; 2012 Mar; 51(3):229-39. PubMed ID: 22072501
[TBL] [Abstract][Full Text] [Related]
5. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
[No Abstract] [Full Text] [Related]
6. Co-expression Analysis of Genes and Tumor-Infiltrating Immune Cells in Metastatic Uterine Carcinosarcoma.
Huang R; Sun H; Yan G; Zhang L; Sun W; Zhang J; Yin H; Xian S; Hu P; Yan P; Zhu X; Meng T; Wang J; Huang Z
Reprod Sci; 2021 Sep; 28(9):2685-2698. PubMed ID: 33905082
[TBL] [Abstract][Full Text] [Related]
7. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract][Full Text] [Related]
8. Classification of serous ovarian carcinoma based on immunogenomic profiling.
Chen P; Zhang Y; Liang C; Yang Y; Li Y; Wan J
Int Immunopharmacol; 2021 Feb; 91():107274. PubMed ID: 33360087
[TBL] [Abstract][Full Text] [Related]
9. Gynecological carcinosarcomas: Overview and future perspectives.
Collet L; González López AM; Romeo C; Méeus P; Chopin N; Rossi L; Rowinski E; Serre AA; Rannou C; Buisson A; Treilleux I; Ray-Coquard I
Bull Cancer; 2023 Nov; 110(11):1215-1226. PubMed ID: 37679206
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
11. Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.
Lakis S; Kotoula V; Koliou GA; Efstratiou I; Chrisafi S; Papanikolaou A; Zebekakis P; Fountzilas G
Cancer Genomics Proteomics; 2020; 17(5):529-541. PubMed ID: 32859631
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted therapies in ovarian and uterine carcinosarcomas.
Han C; Altwerger G; Menderes G; Haines K; Feinberg J; Lopez S; Manzano A; Varughese J; Santin AD
Discov Med; 2018 Jun; 25(140):309-319. PubMed ID: 30021104
[TBL] [Abstract][Full Text] [Related]
13. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas.
Sertier AS; Ferrari A; Pommier RM; Treilleux I; Boyault S; Devouassoux-Shisheboran M; Kielbassa J; Thomas E; Tonon L; Le Texier V; Charreton A; Morel AP; Floquet A; Joly F; Berton-Rigaud D; Ferron G; Arnould L; Croce S; Bataillon G; Saintigny P; Mery-Lamarche E; Sagan C; Senaratne AP; Gut IG; Calvo F; Viari A; Ouzounova M; Ray-Coquard I; Puisieux A
Cancer Res Commun; 2023 May; 3(5):830-841. PubMed ID: 37377900
[TBL] [Abstract][Full Text] [Related]
15. Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.
Hagemann AR; Cadungog M; Hagemann IS; Hammond R; Adams SF; Chu CS; Rubin SC; Zhang L; Addya K; Birrer MJ; Gimotty PA; Coukos G
Cancer Biol Ther; 2011 Aug; 12(4):357-66. PubMed ID: 21785264
[TBL] [Abstract][Full Text] [Related]
16. Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models.
Cuppens T; Depreeuw J; Annibali D; Thomas D; Hermans E; Gommé E; Trinh XB; Debruyne D; Moerman P; Lambrechts D; Amant F
Gynecol Oncol; 2017 Sep; 146(3):538-545. PubMed ID: 28625393
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
Zhou P; Chen D; Zhu B; Chen W; Xie Q; Wang Y; Tan Q; Yuan B; Zuo X; Huang C; Zhu H; Li G
Front Immunol; 2020; 11():594212. PubMed ID: 33552051
[TBL] [Abstract][Full Text] [Related]
19. Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases.
Ikeda K; Tate G; Suzuki T; Mitsuya T
Gynecol Oncol; 2005 May; 97(2):323-9. PubMed ID: 15863125
[TBL] [Abstract][Full Text] [Related]
20. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: clinicoimmunohistochemical and histogenetic characteristics.
Kedzia W; Pruski D; Iwaniec K; Przybylski M; Friebe Z; Rajpert-Kedzia H
Folia Histochem Cytobiol; 2012; 50(4):513-8. PubMed ID: 23264213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
